Sign In
Buy SELB
$0.88
+0 (+0%)
At Close: Feb 12, 2024
Selecta's ImmTOR™ platform enhances transgene expression and addresses adeno-associated virus (AAV) vector immunogenicity constraints to deliver transformative therapies Selecta's ImmTOR™ platform
Selecta Biosciences to Participate in Cantor Virtual Global Healthcare Conference
08:00am, Tuesday, 21'st Sep 2021
WATERTOWN, Mass., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic the
Selecta Biosciences Announces Appointment of Kevin Tan as Chief Financial Officer
08:00am, Monday, 20'th Sep 2021
WATERTOWN, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic the
Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference
08:00am, Thursday, 09'th Sep 2021
WATERTOWN, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic the
Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q2 2021 Results - Earnings Call Transcript
01:27pm, Thursday, 12'th Aug 2021
Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q2 2021 Results - Earnings Call Transcript
Selecta Biosciences: Q2 Earnings Insights
08:14am, Thursday, 12'th Aug 2021
Shares of Selecta Biosciences (NASDAQ:SELB) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were up 100.00% over the past year to $0.00, which beat the estim
New Strong Sell Stocks for July 14th
12:22pm, Wednesday, 14'th Jul 2021
COHU, NTRB, HELE, CNR, and SELB have been added to the Zacks Rank #5 (Strong Sell) List on July 14, 2021
Selecta Biosciences to Participate at the William Blair Biotech Focus Conference 2021
08:00am, Thursday, 08'th Jul 2021
WATERTOWN, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic ther
Selecta Biosciences Has Multiple Shots On Goal
06:51pm, Monday, 28'th Jun 2021
The company offers its ImmTOR platform with its ability to decrease specific immune system responses which can improve the performance of multiple therapies. We like these kinds of 'multiple shots on
Selecta Biosciences Appoints Industry Leader Nishan de Silva, M.D. to Board of Directors
08:00am, Thursday, 24'th Jun 2021
WATERTOWN, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic the
Selecta Biosciences to Participate at the Raymond James Human Health Innovation Conference
08:00am, Wednesday, 16'th Jun 2021
WATERTOWN, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic ther
Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q1 2021 Results - Earnings Call Transcript
01:22pm, Thursday, 13'th May 2021
Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q1 2021 Results - Earnings Call Transcript
Selecta Biosciences, Inc. (SELB) Reports Q1 Loss, Tops Revenue Estimates
12:55pm, Thursday, 13'th May 2021
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -83.33% and 60.54%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the st
Recap: Selecta Biosciences Q1 Earnings
09:50am, Thursday, 13'th May 2021
Shares of Selecta Biosciences (NASDAQ:SELB) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were down 4.76% year over year to ($0.22), which missed the
Why Selecta Biosciences Stock Is Dropping Today
01:06pm, Thursday, 29'th Apr 2021
The progress of one of the company's clinical programs is being delayed.
